Instruction 1(b).

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

•	•		_	•	•••		_	_	•	_	-	 •
V.	as	hin	ntn	n	D	\mathbf{C}	2	054	Q			

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

Chappe (Last)	ell Todd	f Reporting Person*		Issuer Name and Ticker or Trading Symbol Korro Bio, Inc. [KRRO] 3. Date of Earliest Transaction (Month/Day/Year) 11/03/2023								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Chief Operating Officer Chief Operating Officer							
	Í	QUARE, BUILI	DING 600-700		4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person						
(Street)	IDGE	MA	A 02139			Rule 10b5-1(c) Transaction Indication													
(City) (State) (Zip)					Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.														
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3) 2. Transc Date (Month/L					2A. Deemed Execution Date, if any (Month/Day/Year)		Transaction Disposed Code (Instr.		ties Acquired (A) or d Of (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Following R	Form: Owned (D) or leported (I) (Ins		Direct ndirect tr. 4)	. Nature of ndirect Beneficial Ownership				
									v	Amount	(A) (D)	Price		Transaction(s) (Instr. 3 and 4)			(Instr. 4)		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable ar Expiration Date (Month/Day/Year)					8. Price of Derivative Security (Instr. 5)			10. Ownershi Form: Direct (D) or Indirec (I) (Instr. 4	Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisab		xpiration ate	Title	Amount or Number of Shares		(Instr. 4)					
Stock Option (Right to Buy)	\$11.68 ⁽¹⁾⁽²⁾	11/03/2023		A ⁽¹⁾⁽²⁾		13,625 ⁽¹⁾⁽²⁾		(3)	0	3/09/2031	Common Stock	13,625(1)(2)	(1)(2)(4)	13,625		D			
Stock Option (Right to Buy)	\$22.75 ⁽¹⁾⁽²⁾	11/03/2023		A ⁽¹⁾⁽²⁾		4,968 ⁽¹⁾⁽²⁾		(5)	0	1/26/2032	Common Stock	4,968(1)(2)	(1)(2)(6)	4,96	8	D			
Stock Option (Right to Buy)	\$20.94 ⁽¹⁾⁽²⁾	11/03/2023		A ⁽¹⁾⁽²⁾		5,128 ⁽¹⁾⁽²⁾		(7)	0	1/23/2033	Common Stock	5,128 ⁽¹⁾⁽²⁾	(1)(2)(8)	5,128	8	D			
Stock Option (Right to Buy)	\$14.98	11/03/2023		A		62,651		(9)	1	1/02/2033	Common Stock	62,651	\$0.00	62,65	51	D			

Explanation of Responses:

- 1. Under the terms of an Agreement and Plan of Merger dated as of July 14, 2023 by and among Korro Bio Ops, Inc., (f/k/a Korro Bio, Inc., "Legacy Korro"), the Issuer (f/k/a Frequency Therapeutics, Inc.) and Frequency Merger Sub, Inc., a wholly owned subsidiary of the Issuer ("Merger Sub"), on November 3, 2023, Merger Sub merged with and into Legacy Korro (the "Merger"), with Legacy Korro surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, each outstanding option to purchase shares of Legacy Korro common stock issued under the Korro Bio, Inc. 2019 Stock Incentive Plan (the "2019 Plan") was assumed by the Issuer and converted into an option to purchase the Issuer's common stock, at an exchange ratio of 0.049688 per share, on the same terms and conditions as were applicable under the 2019 Plan prior to the Merger, after giving effect to a reverse stock split of the Issuer's common stock of 1-for-50.
- 2. (Continued from footnote 1) Subsequent to the Merger, the name of the Issuer was changed from Frequency Therapeutics, Inc. to Korro Bio, Inc.
- 3. The shares subject to the option vest as to 25% of the shares on March 8, 2022, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
- 4. Received in exchange for a stock option to acquire 274,220 shares of Legacy Korro common stock issued under the 2019 Plan pursuant to the Merger Agreement.
- 5. The shares subject to the option vest as to 25% of the shares on January 27, 2023, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such
- 6. Received in exchange for a stock option to acquire 100,000 shares of Legacy Korro common stock issued under the 2019 Plan pursuant to the Merger Agreement.
- 7. The shares subject to the option vest as to 25% of the shares on January 1, 2024, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such
- 8. Received in exchange for a stock option to acquire 103,223 shares of Legacy Korro common stock issued under the 2019 Plan pursuant to the Merger Agreement.
- 9. The shares subject to the option vest in 48 equal monthly installments commencing from November 3, 2023, subject to the Reporting Person's continued service on each such vesting date.

/s/ Shelby Walker, Attorney-in-11/07/2023 fact

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.